Mammotome has launched Mammotome AutoCore Single Insertion Core Biopsy System, the first automated spring-loaded core needle device on the market.

This innovative launch highlights the company's unwavering dedication to pioneering breast biopsy technology and improving patient care. The Mammotome AutoCore system offers significant advantages over traditional core needle devices, saving valuable time for physicians and improving the patient experience.

Developed with efficiency and ergonomics in mind, the single insertion design simplifies ultrasound-guided biopsies by reducing procedural steps. The system features single-button functionality with automated arming, allowing the user to perform all sampling steps with one button.

This eliminates manual arming and enables easy one-handed operation. Designed for touchless tissue transfer, samples are automatically collected in a clear, illuminated cup positioned in front of the user's hand.

A wiper arm moves each sample from the aperture to the cup, eliminating the need to remove and reinsert the needle between samples. Once all samples are obtained, the tissue collection cup can be removed and placed directly into formalin. This innovation reduces procedural steps and time while allowing physicians to maintain visual focus on the lesion, ensuring precise sampling.

"Mammotome is dedicated to providing innovative solutions that improve the biopsy experience for both patients and physicians," said Karen Isaacs, Vice President of Engineering and R&D at Mammotome.

"The Mammotome AutoCore system is the first core needle device of its kind, bringing in a new era of efficiency for ultrasound core needle breast biopsies. The launch of this device is a testament to our ongoing dedication to innovation and excellence in breast care," said Isaacs.

The Mammotome AutoCore system is now FDA-cleared in the United States and will be available to clinicians domestically in early 2025, with plans to expand to other select countries across the globe.